
Please try another search
On Dec 7, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (NASDAQ:OMCL) . The stock has a Zacks Rank #5 (Strong Sell).
Over the last three months, Omnicell’s shares have been slightly above the broader industry. The stock has gained 0.2% versus the broader industry’s gain of 0.1%.
Omnicell exited third-quarter 2017 on a mixed note with earnings beating the Zacks Consensus Estimate and revenues missing the same. Also, a weak gross margin scenario is a matter of concern. We believe the company’s strategies including portfolio expansion, acquisitions and penetration into the medication adherence market to continue driving expenses. Meanwhile, costs related to the recently launched XT series have been exerting pressure on the bottom line.
Omnicell’s lowering of the upper end of the 2017 adjusted revenue guidance is reflective of the fact that the overall slump will stay to bother. A tough competitive landscape also acts as a dampener.
On a positive note, the year-over-year increase in earnings and revenues was impressive. The company witnessed balanced growth across all business lines in the quarter. We are also encouraged the company’s efforts on product innovation through Research and Development (R&D). Omnicell has of late been observed to gain consistently from a series of product launches (the latest being XT Series Automated Supply Dispensing system) and strategic partnerships.
Stocks to Consider
Some better-ranked medical stocks are PetMed Express, Inc. (NASDAQ:PETS) , Myriad Genetics, Inc. (NASDAQ:MYGN) and Align Technology, Inc. (NASDAQ:ALGN) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 89.2% over a year.
Myriad Genetics has a long-term expected earnings growth rate of 15%. The stock has gained 94.9% in a year.
Align Technologyhas a long-term expected earnings growth rate of 28.9%. The stock has gained 142% in a year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7% and +90.2%, respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Since the Robotaxi event on October 11th, Tesla (NASDAQ:TSLA) stock is up 38%, currently priced at $291.60 per share This is a return to the early November 2024 price level. But...
The Q4 2024 earnings season tapers off from here, with S&P 500® EPS growth surpassing 17%, the highest in 3 years Large cap outlier earnings dates this week include:...
Shares of Alibaba (NYSE:BABA) are on a tear to start off 2025. The consumer discretionary and tech stock is up by 52% this year as of the Feb. 25 close. The company’s cloud...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.